Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.
about
Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates.Peritoneal dissemination of ovarian cancer: role of MUC16-mesothelin interaction and implications for treatment.Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates.Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications.
P2860
Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Phase I study of safety and ph ...... nresectable pancreatic cancer.
@en
Phase I study of safety and ph ...... nresectable pancreatic cancer.
@nl
type
label
Phase I study of safety and ph ...... nresectable pancreatic cancer.
@en
Phase I study of safety and ph ...... nresectable pancreatic cancer.
@nl
prefLabel
Phase I study of safety and ph ...... nresectable pancreatic cancer.
@en
Phase I study of safety and ph ...... nresectable pancreatic cancer.
@nl
P2093
P2860
P356
P1433
P1476
Phase I study of safety and ph ...... nresectable pancreatic cancer.
@en
P2093
H A Burris
J R Infante
P2860
P304
P356
10.1093/ANNONC/MDW401
P577
2016-11-01T00:00:00Z